

PrEP (Pre-exposure Prophylaxis) Algorithm

medication for HIV negative individuals to reduce the risk of HIV infection

Offer to at risk persons:

- Sexually active gay and bisexual men without HIV
- Sexually active heterosexual men and women without HIV
- Sexually active transgender persons without HIV
- Persons without HIV who inject drugs
- Persons with previous non-occupational post-exposure prophylaxis (PEP) use and continued risky behavior, or multiple courses of PEP use

Baseline Testing:

- 4th generation HIV test
 - Add HIV RNA PCR for any concern for recent or acute HIV infection (fever, sore throat, myalgias, abdominal pain, diarrhea, nausea, vomiting, headache.)
- Hepatitis B serology
- Hepatitis A and Hepatitis C antibody
- Creatinine (determine creatinine clearance)
- Pregnancy test for those who are at risk for pregnancy
- STI testing (Syphilis, chlamydia/gonorrhea)
 - In addition to the standard urine test for STI, the provider might also offer to do the local testing when feasible (oral, rectal).

Eligible:

Sexually Active Adults & Adolescents:

- Anal or vaginal sex in past 6 months AND any of the following:
 - HIV positive sexual partner (especially if partner has unknown or detectable viral load)
 - Bacterial STI in past 6 months
 - History of inconsistent or no condom use with sexual partner (s)

Injection drug users:

- HIV positive injecting partner
- Sharing injection equipment

Clinically Eligible:

- Documented negative HIV Ag/Ab test result within 1 week before initially prescribing PrEP
- No signs/symptoms of acute HIV infection
- Estimated creatinine clearance ≥ 30 ml/min⁴
- No contraindicated medications

Medication Options:

Oral vs. Injection

Adults and adolescents weighing at least 35 kg (77 lb).

- Daily oral PrEP with Truvada (FTC/TDF) among all persons at risk through sex or injection drug use.
- Daily oral PrEP with Descovy (FTC/TAF) among persons at risk through sex, **excluding people at risk through receptive vaginal sex.**
 - Descovy has not yet been studied for HIV prevention for receptive vaginal sex.

Adults 18 years of age or older.

- Every two months IM injection with Apretude is recommended to prevent HIV infection among all persons at risk through sex.

Oral PrEP Follow-up:

- Follow-up visits at least every 3 months to provide the following:
 - HIV Ag/Ab test, medication adherence and behavioral risk reduction support
 - Bacterial STI screening for men who have sex with men (MSM) and transgender women who have sex with men - oral, rectal, urine, blood
 - Access to clean needles/syringes and drug treatment services for person with IV drug use (PWID)
- Follow-up visits every 6 months to provide the following:
 - Assess renal function for patients aged ≥ 50 years or who have an eCrCl < 90 ml/min at PrEP initiation
 - Bacterial STI screening for all sexually-active patients - [oral, rectal, urine as indicated], blood
- Follow-up visits every 12 months to provide the following:
 - Assess renal function for all patients
 - Chlamydia screening for heterosexually active women and men - vaginal, urine
 - For patients on FTC/TAF, assess weight, triglyceride and cholesterol levels

Need more information?

Contact PrEP Hotline for CNH

202-476-7779

or e-mail

PrEPServicesSIS@childrensnational.org



Children's National.